Summarized by Masters of Longevity from Neuroscience News.
Targeting brain inflammation via an existing drug class — a concise explainer of a laboratory-to-clinic repurposing story and its clinical potential.
Key Takeaways
- Blocking the P2X7 receptor stopped pro-inflammatory cytokine release in living human brain tissue.
- Researchers replicated the anti-inflammatory effect using human monocyte-derived microglia and neurosurgical brain slices.
- Existing P2X7 antagonist drugs have prior human testing, enabling accelerated repurposing toward trials for neurodegenerative and acute brain disorders.
